Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about treating hair loss without finasteride or dutasteride due to sensitivity causing gynecomastia. The user plans to use pyrilutamide, RU58841, and oral Minoxidil instead.

A user experienced mild side effects from 0.5mg finasteride daily, including increased estradiol and minor gynecomastia. They are considering taking a low dose of exemestane to reduce estrogen levels.

User shares 8-month progress using Fin/Min/Niz and microneedling for hair loss, with positive results and no side effects. Discusses routine, including Fin 1mg daily, Minox 2x daily, Niz 2x weekly, and derma pen 1.5mm weekly.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

The conversation discusses a hair loss protocol and compares it to using finasteride and minoxidil. It suggests that while the protocol includes some good advice, it may not surpass the effectiveness of established treatments like finasteride and minoxidil.

The conversation discusses whether long-term use of finasteride (Fin) is harmful to the liver, with various opinions on side effects and comparisons to other substances. Specific treatments mentioned include finasteride, minoxidil (Min), and RU58841 (RU).

Microneedling and tretinoin may enhance minoxidil absorption for hair loss, but evidence on their effectiveness is limited. Iron supplements and broccoli sprouts are suggested for enzyme activation, but their impact on hair is unclear.

Topical finasteride is considered safer for the liver than oral finasteride due to less systemic absorption, but regular liver function tests are advised. The user is concerned about liver health due to a history of NAFLD and is exploring topical finasteride as a safer alternative.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

The user is using dutasteride, finasteride, and RU58841 for hair loss but is allergic to minoxidil. Suggestions include dropping finasteride, increasing dutasteride dosage, and considering alternatives like microneedling, laser treatments, scalp massage, and supplements.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

Prolonged use of topical minoxidil and finasteride can lead to neuroendocrine and autonomic dysfunction, causing severe sensitivity and side effects. Recovery involves avoiding these treatments, supporting neurosteroid recovery, calming the sympathetic system, and rebuilding scalp health naturally.

Finasteride is a controversial hair loss treatment, with some users experiencing positive results and others facing side effects like erectile dysfunction. The discussion emphasizes the importance of personal choice and informed decision-making.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

Pyrilutamide should not be mixed with Minoxidil because the water in Minoxidil can degrade it. It's suggested to apply Minoxidil first, wait an hour, then apply Pyrilutamide.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

The user is using minoxidil, finasteride, and recently added tretinoin to address hair loss, specifically around a receding hairline. They are seeking advice on application methods and mention experiencing mild skin rashes potentially from tretinoin.

The conversation discusses using a combination of finasteride, spironolactone, minoxidil, retinol, azelaic acid, and caffeine for hair loss treatment. The user inquires about the limitations of these drugs and whether tretinoin would be more effective than retinol.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user experienced sexual side effects from a topical finasteride and minoxidil combo and stopped using it after three weeks. They plan to use foam minoxidil nightly to slow hair loss and seek alternative treatments that don't affect sexual health.

A user is experiencing side effects like less hard erections and sensitive nipples while on finasteride, with bloodwork showing high prolactin levels. They are seeking suggestions to address the prolactin issue.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.